StreetInsider.com News Articles

Form 8-K Citius Pharmaceuticals, For: Oct 26

Mon, 26 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261026/27234039.html

Form 8-K CITIUS ONCOLOGY, INC. For: Oct 26

Mon, 26 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261026/27234037.html

Form 8-K CITIUS ONCOLOGY, INC. For: Oct 26

Mon, 26 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261026/27234037.html

Citius Oncology LYMPHIR wholesaler units rise 120% in Q4 2026

Mon, 26 Oct 2026 13:02:29 -0400

Citius Oncology, Inc. (NASDAQ: CTOR) reported preliminary, unaudited data showing that U.S. wholesaler purchases of LYMPHIR® (denileukin diftitox-cxdl) reached 792 units in the fiscal fourth quarter ended September 30, 2026, up 120% from 360 units in the prior quarter ended June 30, 2026.

Prescribing centers ordered 950 LYMPHIR vials from wholesalers during the fiscal fourth quarter, compared with 926 in the fiscal third quarter. The number of institutions that have ordered LYMPHIR rose to 54 as of the release date, up from 44 as of August 14, 2026.

"The fiscal fourth quarter showed continued institutional demand for LYMPHIR. Unit sales to wholesalers

Citius Oncology LYMPHIR wholesaler units rise 120% in Q4 2026

Mon, 26 Oct 2026 13:02:29 -0400

"The fiscal fourth quarter showed continued institutional demand for LYMPHIR. Unit sales to wholesalers

Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026

Mon, 26 Oct 2026 13:00:00 -0400

CRANFORD, N.J., Oct. 26, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced preliminary, unaudited LYMPHIR^® (denileukin diftitox-cxdl) unit sales to U.S. wholesalers and institutional vial orders for the fiscal fourth quarter ended September 30, 2026.

Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026

Mon, 26 Oct 2026 13:00:00 -0400

Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026

Mon, 26 Oct 2026 13:00:00 -0400

Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026

Mon, 26 Oct 2026 13:00:00 -0400

Form 8-K CITIUS ONCOLOGY, INC. For: Oct 19

Fri, 23 Oct 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20261023/27227970.html

Form 8-K CITIUS ONCOLOGY, INC. For: Oct 19

Fri, 23 Oct 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20261023/27227970.html

Citius Pharmaceuticals to Participate in October 2026 Investor Conferences

Mon, 12 Oct 2026 08:30:00 -0400

Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the 2026 Maxim Growth Summit and the ThinkEquity Conference

CRANFORD, N.J., Oct. 12, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and Chief

Citius Pharmaceuticals to Participate in October 2026 Investor Conferences

Mon, 12 Oct 2026 08:30:00 -0400

Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the 2026 Maxim Growth Summit and the ThinkEquity Conference

Citius Pharmaceuticals to Participate in October 2026 Investor Conferences

Mon, 12 Oct 2026 08:30:00 -0400

Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the 2026 Maxim Growth Summit and the ThinkEquity Conference

Citius Pharmaceuticals to Participate in October 2026 Investor Conferences

Mon, 12 Oct 2026 08:30:00 -0400

Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the 2026 Maxim Growth Summit and the ThinkEquity Conference

Form 8-K CITIUS ONCOLOGY, INC. For: Sep 29

Tue, 29 Sep 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260929/27122926.html

Form 8-K CITIUS ONCOLOGY, INC. For: Sep 29

Tue, 29 Sep 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260929/27122926.html

Form ARS CITIUS ONCOLOGY, INC. For: Sep 30

Wed, 26 Aug 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260826/26978164.html

Form ARS CITIUS ONCOLOGY, INC. For: Sep 30

Wed, 26 Aug 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260826/26978164.html

Form ARS CITIUS ONCOLOGY, INC. For: Sep 30

Wed, 26 Aug 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260826/26978164.html

Form ARS CITIUS ONCOLOGY, INC. For: Sep 30

Wed, 26 Aug 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260826/26978164.html

Form DEF 14A CITIUS ONCOLOGY, INC. For: Sep 29

Wed, 26 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260826/26978117.html

Form DEF 14A CITIUS ONCOLOGY, INC. For: Sep 29

Wed, 26 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260826/26978117.html

Form DEF 14A CITIUS ONCOLOGY, INC. For: Sep 29

Wed, 26 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260826/26978117.html

Form DEF 14A CITIUS ONCOLOGY, INC. For: Sep 29

Wed, 26 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260826/26978117.html